Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Syndax Pharmaceuticals IncSNDX · Entity 4578 | Director | May 23, 2018 | May 25, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Syndax Pharmaceuticals Inc
Report date May 23, 2018 · Filed May 25, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.93 · Expires 2028-05-23 | Direct | 14,000 |
Reported balance
After 2018-05-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-05-23 · Grant · Acquired 14,000 · Balance 14,000 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 23, 2018 Filed May 25, 2018 09:00 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | GrantStock Option (Right to Buy) · Derivative | 14,000 | $0.00 Strike: $8.93 | $0.00 |
DisclosureSEC source: 0001562180-18-002685 · primarydocument.xml · derivative · entry 1 Chen Henry · CIK 0001667481 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock · 14,000 shares Expires 2028-05-23 Read SEC document |
| February 08, 2018 Filed Feb 12, 2018 16:00 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $9.63 | $0.00 |
DisclosureSEC source: 0001562180-18-000718 · primarydocument.xml · derivative · entry 1 Chen Henry · CIK 0001667481 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2028-02-08 F1 · derivative.exercise_date: 1/36th of the shares subject to the option shall vest monthly over a three-year period. Read SEC document |
| May 17, 2017 Filed May 19, 2017 11:26 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | GrantStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $13.58 | $0.00 |
DisclosureSEC source: 0001562180-17-002004 · primarydocument.xml · derivative · entry 2 Chen Henry · CIK 0001667481 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2027-05-17 F1 · derivative.exercise_date: 1/36th of the shares subject to the option shall vest monthly over a three-year period. Read SEC document |
| May 17, 2017 Filed May 19, 2017 11:26 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $13.58 | $0.00 |
DisclosureSEC source: 0001562180-17-002004 · primarydocument.xml · derivative · entry 1 Chen Henry · CIK 0001667481 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2027-05-17 Read SEC document |
| October 31, 2016 Filed Nov 2, 2016 17:25 UTC | Syndax Pharmaceuticals Inc SNDX · Entity 4578 | GrantStock Options (Right to buy) · Derivative | 8,000 | $0.00 Strike: $11.81 | $0.00 |
DisclosureSEC source: 0001562180-16-003358 · primarydocument.xml · derivative · entry 1 Chen Henry · CIK 0001667481 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires 2026-10-31 F1 · derivative.exercise_date: One hundred percent (100%) of the total number of shares underlying the option shall vest on October 31, 2017, subject to the reporting person's continuous service through the vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.